“Great product, you almost notice immediate impact on patient. It’s a highly specialty product,
hugh medical need for it but it’s quite expensive. How best to approach the PBS submission? Who can help us?”
CEO of Global Pharmaco

 

Case: Specialty product pricing

Focus:

Medical need; S100 category; pre-meetings with KOLs and Authority; global price and reimbursement status; risk/benefit price analysis; RSA (Risk Share Agreement)

Outcome:

• Acceptance, positive feedback and support for price submission from KOLs
• Effective cooperation of global and national pricing managers
• Strategic input and feedback from pre-meetings
• Substantiated price submission on time
• RSA negotiations
• Reimbursement in second attempt (above average)